Unaudited Financial Results for the Quarter ended on June 30, 2025
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech's Board approved unaudited standalone and consolidated results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations fell to ₹38.45 crore from ₹41.48 crore a year ago, a decline of about 7.3%, and standalone net profit dropped to ₹1.64 crore from ₹2.26 crore, down roughly 27.5%. Consolidated revenue was nearly flat at ₹43.04 crore, but consolidated net profit rose to ₹1.60 crore from ₹1.35 crore, up about 18.4%. A notable one-time charge of ₹1.88 crore (commercial tax expenses related to earlier years) is shown as an exceptional item, and before this charge, the company actually slipped into a loss of ₹1.88 crore at the operating level. The auditor (Rai Qimat & Associates) issued an unmodified limited review opinion on both results. The Board also recommended a final dividend of ₹1 per share (10%) for FY25, set the 32nd AGM for September 26, 2025, and approved the appointment of an Executive Director and two new Independent Directors.
Standalone top-line and profit declined year-on-year, and a ₹1.88 crore exceptional commercial tax charge from earlier years pushed the pre-exceptional result into a loss, which is a negative signal for core Q1 profitability. The proposed ₹1 per share dividend and stable consolidated picture offer some support, but shareholders should watch for margin recovery and clarity on whether similar past tax exposures could recur.